Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 15

1.

A pooled mutational analysis identifies ionizing radiation-associated mutational signatures conserved between mouse and human malignancies.

Davidson PR, Sherborne AL, Taylor B, Nakamura AO, Nakamura JL.

Sci Rep. 2017 Aug 9;7(1):7645. doi: 10.1038/s41598-017-07888-0.

2.
3.

Monoallelic loss of the imprinted gene Grb10 promotes tumor formation in irradiated Nf1+/- mice.

Mroue R, Huang B, Braunstein S, Firestone AJ, Nakamura JL.

PLoS Genet. 2015 May 22;11(5):e1005235. doi: 10.1371/journal.pgen.1005235. eCollection 2015 May. Erratum in: PLoS Genet. 2015 Jun;11(6):e1005327.

4.

The NF1 gene revisited - from bench to bedside.

Yap YS, McPherson JR, Ong CK, Rozen SG, Teh BT, Lee AS, Callen DF.

Oncotarget. 2014 Aug 15;5(15):5873-92. Review.

5.

Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke.

North M, Shuga J, Fromowitz M, Loguinov A, Shannon K, Zhang L, Smith MT, Vulpe CD.

BMC Cancer. 2014 Jan 5;14:6. doi: 10.1186/1471-2407-14-6.

6.

SWR/J mice are susceptible to alkylator-induced myeloid leukemia.

Janke MR, Baty JD, Graubert TA.

Blood Cancer J. 2013 Nov 15;3:e161. doi: 10.1038/bcj.2013.59. No abstract available.

7.

Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms.

Choi G, Huang B, Pinarbasi E, Braunstein SE, Horvai AE, Kogan S, Bhatia S, Faddegon B, Nakamura JL.

Cancer Res. 2012 Dec 15;72(24):6425-34. doi: 10.1158/0008-5472.CAN-12-1728. Epub 2012 Oct 15.

8.

Loss of tumor suppressor NF1 activates HSF1 to promote carcinogenesis.

Dai C, Santagata S, Tang Z, Shi J, Cao J, Kwon H, Bronson RT, Whitesell L, Lindquist S.

J Clin Invest. 2012 Oct;122(10):3742-54. doi: 10.1172/JCI62727. Epub 2012 Sep 4.

9.

Targeting oncogenic Ras signaling in hematologic malignancies.

Ward AF, Braun BS, Shannon KM.

Blood. 2012 Oct 25;120(17):3397-406. doi: 10.1182/blood-2012-05-378596. Epub 2012 Aug 16. Review.

10.

Second malignant neoplasms and cardiovascular disease following radiotherapy.

Travis LB, Ng AK, Allan JM, Pui CH, Kennedy AR, Xu XG, Purdy JA, Applegate K, Yahalom J, Constine LS, Gilbert ES, Boice JD Jr.

J Natl Cancer Inst. 2012 Mar 7;104(5):357-70. doi: 10.1093/jnci/djr533. Epub 2012 Feb 6. Review.

11.

Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.

Nakamura JL, Phong C, Pinarbasi E, Kogan SC, Vandenberg S, Horvai AE, Faddegon BA, Fiedler D, Shokat K, Houseman BT, Chao R, Pieper RO, Shannon K.

Cancer Res. 2011 Jan 1;71(1):106-15. doi: 10.1158/0008-5472.CAN-10-2732.

12.

NF1 inactivation in adult acute myelogenous leukemia.

Parkin B, Ouillette P, Wang Y, Liu Y, Wright W, Roulston D, Purkayastha A, Dressel A, Karp J, Bockenstedt P, Al-Zoubi A, Talpaz M, Kujawski L, Liu Y, Shedden K, Shakhan S, Li C, Erba H, Malek SN.

Clin Cancer Res. 2010 Aug 15;16(16):4135-47. doi: 10.1158/1078-0432.CCR-09-2639. Epub 2010 May 26.

13.

Therapy-related myelodysplastic syndrome: models and genetics.

Graubert T.

Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S45-7. doi: 10.1016/j.bbmt.2009.10.019. Epub 2009 Oct 24. Review. No abstract available.

14.

Survival and tumorigenesis in O6-methylguanine DNA methyltransferase-deficient mice following cyclophosphamide exposure.

Nagasubramanian R, Hansen RJ, Delaney SM, Cherian MM, Samson LD, Kogan SC, Dolan ME.

Mutagenesis. 2008 Sep;23(5):341-6. doi: 10.1093/mutage/gen018. Epub 2008 May 13.

15.

Abnormal hematopoiesis in Gab2 mutant mice.

Zhang Y, Diaz-Flores E, Li G, Wang Z, Kang Z, Haviernikova E, Rowe S, Qu CK, Tse W, Shannon KM, Bunting KD.

Blood. 2007 Jul 1;110(1):116-24. Epub 2007 Mar 20.

Supplemental Content

Support Center